Ani Pharmaceuticals (ANIP) Convertible Debt (2010 - 2019)

Ani Pharmaceuticals has disclosed Convertible Debt across 9 years of filings, most recently posting $117.6 million for Q3 2019.

• Convertible Debt for Q3 2019 came in at $117.6 million, down 12.33% year-over-year; the trailing twelve-month figure through Sep 2019 was $117.6 million (down 12.33% YoY), and the FY2018 annual result was $112.5 million, down 12.28% from the prior year.
• Convertible Debt came in at $117.6 million for Q3 2019 at Ani Pharmaceuticals, up from $115.9 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $134.1 million in Q3 2018 to a low of $112.2 million in Q1 2015.
• The 5-year median for Convertible Debt is $117.6 million (2019), against an average of $120.2 million.
• Across the five-year window, Convertible Debt advanced 6.46% in 2015 and slipped 12.33% in 2019, its largest moves.
• Ani Pharmaceuticals' Convertible Debt stood at $113.4 million in 2015, then gained by 6.36% to $120.6 million in 2016, then advanced by 6.27% to $128.2 million in 2017, then dropped by 12.28% to $112.5 million in 2018, then increased by 4.56% to $117.6 million in 2019.
• The last three Convertible Debt figures came in at $117.6 million (Q3 2019), $115.9 million (Q2 2019), and $114.2 million (Q1 2019), per Business Quant data.